Raymond James analyst Jayson Bedford upgraded Stryker to 'outperform' and set a $418 price target, driving a 3.2% rally in the shares. Bedford cited five consecutive years of organic revenue growth exceeding 10% through 2025 and lauded Stryker’s sustained market share gains in MedTech. He noted that the stock’s forward P/E multiple contracted by roughly three turns over the past year—from more than 26x to near 23x—despite the company maintaining a double-digit growth profile. Bedford projects upside to consensus estimates and argues the valuation reset is unwarranted given Stryker’s operational momentum and high-margin product mix.

Not all investors agree with Bedford’s thesis. Critics point out that Stryker trades at 46x trailing GAAP earnings—an elevated multiple for a company targeting 10% annual earnings expansion. They argue that such a premium valuation leaves limited margin for error if growth slows or if cost pressures intensify in 2026. With a gross margin above 62% and a dividend yield near 1%, the bears concede Stryker’s profitability is robust but contend a valuation contraction is more realistic than further multiple expansion. Several sell-side strategists have trimmed their ratings, warning that upside from current levels is modest unless Stryker accelerates beyond consensus projections.

Stryker will release its fourth quarter and full year 2025 results on January 29, followed by a 4:30 p.m. webcast. The company declared a quarterly dividend of $0.88 per share, payable on January 30, and announced the appointment of Spencer Stiles as President and Chief Operating Officer. Investors will closely scrutinize guidance for 2026, particularly organic revenue targets in MedSurg and Orthopaedics, where pricing and procedure volumes remain key drivers. Management’s outlook on R&D investment and expected synergies from recent acquisitions will also be in focus.

The contrasting viewpoints underscore a critical decision point for investors. Proponents of Stryker’s long-term thesis emphasize its proven track record of innovation across Neurotechnology and joint replacement, a global footprint serving over 150 million patients annually, and a strong balance sheet. Skeptics caution that paying near 50x earnings for mid-teens growth could leave returns vulnerable if execution falters. With the upcoming earnings release and leadership transition, market participants will be watching for clarity on margin expansion, pricing dynamics, and capital allocation priorities to assess whether Stryker’s valuation premium remains justified.